Multicenter Real-World Study of Hyperthermia in Skin/Mucosal HPV Infection of Special Population

Launched by FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITY · Feb 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called hyperthermia, which uses higher temperatures (39-45℃) to help the body fight off viral warts caused by the human papillomavirus (HPV). Previous studies have shown that this method can effectively remove warts, especially for patients who may have difficulty with traditional treatments. The focus of this research is on special groups of people, such as pregnant women, children, and those with certain health conditions like autoimmune diseases or diabetes, who may have more stubborn warts.

Eligible participants for this study include pregnant women, children with viral warts, patients with autoimmune diseases or diabetes, and those taking medications that suppress their immune system. If you or a loved one qualifies, you can expect to receive hyperthermia treatment, which aims to boost the body’s immune response to help clear the warts. The study is currently recruiting participants and aims to better understand how effective and safe this treatment is for these specific populations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Pregnant women with viral warts
• • 2. Diagnosis of AIDS with viral warts
• • 3. Autoimmune disease patients with viral warts
• • 4. Diabetic patients with viral warts
• • 5. Patients with viral warts who are currently being treated with immunosuppressants
• • 6. Children with viral warts
• • 7. The subject or legal guardian is able to understand and sign the informed consent/consent to participate in the study
• Exclusion Criteria:
• • 1. The subject suffers from tumor or other serious disease and cannot complete this clinical study
• • 2. Timely treatment and follow-up cannot be guaranteed due to personal or other objective reasons